肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2008年
10期
676-678
,共3页
杨凤姣%吴湘纬%胡炳强%Touboul E
楊鳳姣%吳湘緯%鬍炳彊%Touboul E
양봉교%오상위%호병강%Touboul E
肛门肿瘤%癌,鳞状细胞%结直肠外科手术%放射疗法%药物疗法%治疗结果%预后
肛門腫瘤%癌,鱗狀細胞%結直腸外科手術%放射療法%藥物療法%治療結果%預後
항문종류%암,린상세포%결직장외과수술%방사요법%약물요법%치료결과%예후
Anus neoplasms%Carcinoma,squamous cell%Colorectal surgery%Radiotherapy%Drug therapy%Treatment outcome%Prognosis
目的 分析肛管癌放化疗的长期疗效和影响预后的因素.方法 对1984年至2005年单纯放疗、放化疗同步治疗的286例肛管鳞状上皮细胞癌患者临床资料进行分析.结果 平均随访期65个月.5年总生存率66.4%,无瘤生存率64.8%,无复发生存率67%.影响无病生存率的因素:肿瘤大小(<40mm)(RR2.1),区域淋巴结转移(RR2.4),第一阶段放疗肿瘤消退情况(>75%)(RR1.9);5年局部控制率为71%,Ⅰ、Ⅱ、ⅢA、ⅢB期患者分别为88%、69%、77%、60%.影响局控率的因素为:肿瘤大小(RR 2.5)、第一阶段放疗肿瘤消退情况(RR 2.4).结论 肿瘤大小、临床分期、第一阶段放疗肿瘤消退情况是影响患者局部控制率、总生存率、无瘤生存率的主要因素.
目的 分析肛管癌放化療的長期療效和影響預後的因素.方法 對1984年至2005年單純放療、放化療同步治療的286例肛管鱗狀上皮細胞癌患者臨床資料進行分析.結果 平均隨訪期65箇月.5年總生存率66.4%,無瘤生存率64.8%,無複髮生存率67%.影響無病生存率的因素:腫瘤大小(<40mm)(RR2.1),區域淋巴結轉移(RR2.4),第一階段放療腫瘤消退情況(>75%)(RR1.9);5年跼部控製率為71%,Ⅰ、Ⅱ、ⅢA、ⅢB期患者分彆為88%、69%、77%、60%.影響跼控率的因素為:腫瘤大小(RR 2.5)、第一階段放療腫瘤消退情況(RR 2.4).結論 腫瘤大小、臨床分期、第一階段放療腫瘤消退情況是影響患者跼部控製率、總生存率、無瘤生存率的主要因素.
목적 분석항관암방화료적장기료효화영향예후적인소.방법 대1984년지2005년단순방료、방화료동보치료적286례항관린상상피세포암환자림상자료진행분석.결과 평균수방기65개월.5년총생존솔66.4%,무류생존솔64.8%,무복발생존솔67%.영향무병생존솔적인소:종류대소(<40mm)(RR2.1),구역림파결전이(RR2.4),제일계단방료종류소퇴정황(>75%)(RR1.9);5년국부공제솔위71%,Ⅰ、Ⅱ、ⅢA、ⅢB기환자분별위88%、69%、77%、60%.영향국공솔적인소위:종류대소(RR 2.5)、제일계단방료종류소퇴정황(RR 2.4).결론 종류대소、림상분기、제일계단방료종류소퇴정황시영향환자국부공제솔、총생존솔、무류생존솔적주요인소.
Objective To analyze the long-term results and prognostic factors of the anal canal cancer after conservative treatment. Methods From 1984 to 2005,286 patients were treated by exclusive radiotherapy or chemoradiotherapy for an epidermoid cancer of anal canal. Results The mean follow-up was 65 months. The 5-year-overall survival and 5-year disease free survival rate were 66.4 % and 64.8 % respectively. In multivariate analysis, the tumor size(<40 mm) (RR 2.1), node involvement (RR 2.4), and poor response(>75 %) to first course irradiation (RR 1.9) were factors for disease free survival (DFS). Five-year-locoreginal control rate (LRC) was 71.5 % (88 % for stage Ⅰ, 69 % for stage Ⅱ, 77 % for stage ⅢA and 60 % for stage ⅢB). Prognostic factors of LRC were tumor size (RR 2.5), response to first course of irradiation (RR 2.9). Conclusion The prognostic factors of the rate of LRC, DFS and global survival assessed by statistical analysis are clinical stage, tumor size and response to first course of irradiation.
